Halozyme Therapeutics, Inc.
IT ˙ BIT ˙ US40637H1095
58,52 € 0,00 (0,00%)
2026-06-03
DEL PRIS
SecurityIT:1HALO / Halozyme Therapeutics, Inc.
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership1,868,708 shares
Latest Disclosed Value $ 120,774,599
D. E. Shaw & Co., Inc. ownership in 1HALO / Halozyme Therapeutics, Inc.

On May 15, 2026 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 1,868,708 shares of Halozyme Therapeutics, Inc. (IT:1HALO) valued at $100,872,858 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,649,466 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of 13.29% during the quarter. The current value of the position is $109,356,792 USD.

D. E. Shaw & Co., Inc. has a history of taking positions in derivatives of the underlying security (1HALO) in the form of stock options. The firm currently holds call options representing 20,900 of underlying shares valued at $1,350,767 USD and put options representing 9,800 of underlying shares valued at $633,374 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

IT:1HALO / Halozyme Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,868,708 219,242 13.29 120,775 8.80 0.0533
2026-02-17 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,649,466 -1,000,909 -37.76 111,009 -42.89 0.0609
2025-11-14 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,650,375 1,631,571 160.15 194,379 266.76 0.1097
2025-08-14 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 1,018,804 399,242 64.44 52,998 34.06 0.0376
2025-05-15 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 619,562 -211,852 -25.48 39,534 -0.54 0.0352
2025-02-14 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 831,414 524,802 171.16 39,750 126.49 0.0292
2024-11-14 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 306,612 -172,163 -35.96 17,550 -29.99 0.0151
2024-08-14 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 478,775 180,650 60.60 25,069 106.71 0.0234
2024-05-15 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 298,125 272,549 1,065.64 12,128 1,183.28 0.0104
2024-02-14 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 25,576 3,527 16.00 945 12.23 0.0008
2023-11-14 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 22,049 10,849 96.87 842 108.93 0.0009
2023-08-14 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 11,200 -15,686 -58.34 404 -60.72 0.0004
2023-05-15 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 26,886 -3,499 -11.52 1,027 -40.62 0.0011
2023-02-14 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 30,385 3,368 12.47 1,729 61.80 0.0019
2022-11-14 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 27,017 2,917 12.10 1,068 0.75 0.0013
2022-08-15 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 24,100 -10,573 -30.49 1,060 -23.36 0.0012
2022-05-16 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 34,673 -193,434 -84.80 1,383 -84.92 0.0013
2022-02-14 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 228,107 1,796 0.79 9,172 -0.37 0.0076
2021-11-15 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 226,311 -211,087 -48.26 9,206 -53.65 0.0083
2021-08-16 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 437,398 -431,065 -49.64 19,862 -45.14 0.0171
2021-05-17 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 868,463 -425,741 -32.90 36,207 -34.50 0.0350
2021-02-16 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,294,204 -1,078,709 -45.46 55,276 -11.36 0.0494
2020-11-16 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,372,913 272,027 12.95 62,360 10.71 0.0638
2020-08-14 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 2,100,886 197,293 10.36 56,325 64.48 0.0671
2020-05-15 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 1,903,593 -171,630 -8.27 34,245 -6.93 0.0534
2020-02-14 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 2,075,223 1,526,558 278.23 36,794 332.36 0.0421
2019-11-14 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 548,665 -4,721 -0.85 8,510 -10.49 0.0105
2019-08-14 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 553,386 233,400 72.94 9,507 84.53 0.0119
2019-05-15 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 319,986 -82,898 -20.58 5,152 -12.59 0.0067
2019-02-14 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 402,884 32,721 8.84 5,894 -12.36 0.0081
2018-11-14 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 370,163 169,425 84.40 6,725 98.61 0.0081
2018-08-14 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 200,738 129,054 180.03 3,386 141.17 0.0044
2018-05-15 2018-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 71,684 -181,052 -71.64 1,404 -72.58 0.0019
2018-02-14 2017-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 252,736 -124,620 -33.02 5,120 -21.89 0.0071
2017-11-14 2017-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 377,356 366,302 3,313.75 6,555 4,516.20 0.0101
2017-08-14 2017-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 11,054 11,054 142 0.0002
2017-05-15 2017-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -10,112 -100.00 0 -100.00
2017-02-14 2016-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 10,112 -60,279 -85.63 100 -88.24 0.0002
2016-11-14 2016-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 70,391 70,391 0.00 850 0.0015
2016-05-16 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 0 -79,095 -100.00 0 -100.00
2016-02-16 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 79,095 -21,890 -21.68 1,371 1.11 0.0020
2015-11-16 2015-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 100,985 -63,495 -38.60 1,356 -63.49 0.0020
2015-08-14 2015-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 164,480 108,969 196.30 3,714 368.35 0.0055
2015-05-15 2015-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 55,511 17,291 45.24 793 114.91 0.0012
2015-02-17 2014-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 38,220 15,400 67.48 369 77.40 0.0005
2014-11-14 2014-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 22,820 -32,480 -58.73 208 -61.90 0.0003
2014-08-14 2014-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 55,300 43,300 360.83 546 259.21 0.0007
2014-05-15 2014-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 12,000 12,000 152 0.0002
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F HALOZYME THERAPEUTICS COM Call 20,900 1,351 n/a n/a n/a
2015-08-14 2015-06-30 13F HALOZYME THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2015-05-15 2015-03-31 13F HALOZYME THERAPEUTICS COM Call 53,000 757 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F HALOZYME THERAPEUTICS COM Put 9,800 633 n/a n/a n/a
2018-08-14 2018-06-30 13F HALOZYME THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2018-05-15 2018-03-31 13F HALOZYME THERAPEUTICS COM Put 15,000 -83.33 294 -83.87 n/a n/a n/a
2018-02-14 2017-12-31 13F HALOZYME THERAPEUTICS COM Put 90,000 1,823 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.